Table 4 Hazard ratios of each parameter to overall survival.

From: Clinical outcomes of endocrine and other disorders induced by immune checkpoint inhibitors in Japanese patients

Parameter

Hazard ratio

95% CI

Age

  

 Under 50 years

1.000

 

 60–69 years

1.017

0.780–1.335

 70–79 years

1.284

1.000–1.662

 Over 80 years

1.428

1.019–1.993

Sex

  

 Male

1.000

 

 Female

1.023

0.796–1.199

Each irAE

  

 Non-irAE

1.000

 

 E-irAE

0.611

0.480–0.772

 O-irAE

0.758

0.597–0.957

 EO-irAE

0.622

0.466–0.819

 ME-irAE

0.463

0.257–0.775

Immune checkpoint inhibitor

  

 Ipilimumab/PD-1 inhibitor

1.000

 

 PD-1 inhibitor

0.780

0.498–1.261

 PD-L1 inhibitor

0.897

0.522–1.567

History of chemotherapy

  

 Without

1.000

 

 With

0.972

0.799–1.186

History of radiation therapy

  

 Without

1.000

 

 With

1.012

0.812–1.258

  1. Data are presented as median (IQR). 95%CI; 95% confidence interval, irAE; immune-related adverse events, E-irAE; endocrine-related irAE, O-irAE; other irAE, EO-irAE; endocrine-related and other irAE, ME-irAE; multiple endocrine-related irAE, PD-1; programmed cell death protein 1, PD-L1; programmed cell death protein 1 ligand 1. The hazard ratio was calculated using a dummy variable.
Back to article page